Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.

Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B.

Target Oncol. 2019 Oct;14(5):563-575. doi: 10.1007/s11523-019-00662-4.

PMID:
31429028
2.

GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.

Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL.

Mol Cancer Res. 2019 Jul;17(7):1503-1518. doi: 10.1158/1541-7786.MCR-18-1121. Epub 2019 Apr 18.

PMID:
31000582
3.

A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, Sandusky G, Stemmer-Rachamimov A, Stuhlmiller TJ, Angus SP, Johnson GL, Nalepa G, Yates CW, Wade Clapp D, Park SJ.

Hum Mol Genet. 2019 Feb 15;28(4):572-583. doi: 10.1093/hmg/ddy361.

PMID:
30335132
4.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium.

Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046.

5.

Engineering a Protein Binder Specific for p38α with Interface Expansion.

Hussain M, Angus SP, Kuhlman B.

Biochemistry. 2018 Jul 31;57(30):4526-4535. doi: 10.1021/acs.biochem.8b00408. Epub 2018 Jul 19.

6.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

7.

Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer.

Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM.

Oncotarget. 2018 Jan 29;9(21):15480-15497. doi: 10.18632/oncotarget.24337. eCollection 2018 Mar 20.

8.

New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.

Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, Johnson GL, Bear JE.

Cancer Res. 2018 Jan 15;78(2):542-557. doi: 10.1158/0008-5472.CAN-17-1653. Epub 2017 Nov 27.

9.

Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.

Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC.

J Am Heart Assoc. 2017 Oct 19;6(10). pii: e006635. doi: 10.1161/JAHA.117.006635.

10.

Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.

Angus SP, Zawistowski JS, Johnson GL.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:209-229. doi: 10.1146/annurev-pharmtox-010617-052954. Epub 2017 Sep 15. Review.

PMID:
28934561
11.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

12.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.

13.

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL.

Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9.

14.

Redefining the MED13L syndrome.

Adegbola A, Musante L, Callewaert B, Maciel P, Hu H, Isidor B, Picker-Minh S, Le Caignec C, Delle Chiaie B, Vanakker O, Menten B, Dheedene A, Bockaert N, Roelens F, Decaestecker K, Silva J, Soares G, Lopes F, Najmabadi H, Kahrizi K, Cox GF, Angus SP, Staropoli JF, Fischer U, Suckow V, Bartsch O, Chess A, Ropers HH, Wienker TF, Hübner C, Kaindl AM, Kalscheuer VM.

Eur J Hum Genet. 2015 Oct;23(10):1308-17. doi: 10.1038/ejhg.2015.26. Epub 2015 Mar 11.

15.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

16.

MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis.

Pham TT, Angus SP, Johnson GL.

Genes Cancer. 2013 Nov;4(11-12):419-26. doi: 10.1177/1947601913513950.

17.

FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.

Shats I, Gatza ML, Liu B, Angus SP, You L, Nevins JR.

Cancer Res. 2013 Oct 1;73(19):6056-67. doi: 10.1158/0008-5472.CAN-13-0453. Epub 2013 Aug 21.

18.

Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression.

Liu B, Shats I, Angus SP, Gatza ML, Nevins JR.

J Biol Chem. 2013 Aug 23;288(34):24581-9. doi: 10.1074/jbc.M113.467506. Epub 2013 Jul 13.

19.

A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest.

Angus SP, Nevins JR.

Oncogene. 2012 Nov 1;31(44):4709-17. doi: 10.1038/onc.2011.622. Epub 2012 Jan 16.

20.

Retinoblastoma/p107/p130 pocket proteins: protein dynamics and interactions with target gene promoters.

Stengel KR, Thangavel C, Solomon DA, Angus SP, Zheng Y, Knudsen ES.

J Biol Chem. 2009 Jul 17;284(29):19265-71. doi: 10.1074/jbc.M808740200. Epub 2009 Mar 11.

21.

Analysis of RB action in DNA damage checkpoint response.

Mayhew CN, Bosco EE, Solomon DA, Knudsen ES, Angus SP.

Methods Mol Biol. 2004;281:3-16.

PMID:
15220518
22.

RB reversibly inhibits DNA replication via two temporally distinct mechanisms.

Angus SP, Mayhew CN, Solomon DA, Braden WA, Markey MP, Okuno Y, Cardoso MC, Gilbert DM, Knudsen ES.

Mol Cell Biol. 2004 Jun;24(12):5404-20.

23.

Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1.

Gunawardena RW, Siddiqui H, Solomon DA, Mayhew CN, Held J, Angus SP, Knudsen ES.

J Biol Chem. 2004 Jul 9;279(28):29278-85. Epub 2004 Apr 22.

24.

Retinoblastoma tumor suppressor: analyses of dynamic behavior in living cells reveal multiple modes of regulation.

Angus SP, Solomon DA, Kuschel L, Hennigan RF, Knudsen ES.

Mol Cell Biol. 2003 Nov;23(22):8172-88.

25.

Functional analysis of the antimitogenic activity of tumor suppressors.

Knudsen ES, Angus SP.

Methods Mol Biol. 2003;218:3-15.

PMID:
12616708
26.

Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action.

Markey MP, Angus SP, Strobeck MW, Williams SL, Gunawardena RW, Aronow BJ, Knudsen ES.

Cancer Res. 2002 Nov 15;62(22):6587-97.

27.

Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication.

Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES.

J Biol Chem. 2002 Nov 15;277(46):44376-84. Epub 2002 Sep 6.

28.

Active RB elicits late G1/S inhibition.

Angus SP, Fribourg AF, Markey MP, Williams SL, Horn HF, DeGregori J, Kowalik TF, Fukasawa K, Knudsen ES.

Exp Cell Res. 2002 Jun 10;276(2):201-13.

PMID:
12027450
29.

Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling.

Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, Knudsen KE, Kowalik TF, Weissman BE, Knudsen ES.

J Biol Chem. 2002 Feb 15;277(7):4782-9. Epub 2001 Nov 21.

30.

Targeted gene knockout of inner arm 1 in Tetrahymena thermophila.

Angus SP, Edelmann RE, Pennock DG.

Eur J Cell Biol. 2001 Jul;80(7):486-97.

PMID:
11499791
31.

Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase.

Sever-Chroneos Z, Angus SP, Fribourg AF, Wan H, Todorov I, Knudsen KE, Knudsen ES.

Mol Cell Biol. 2001 Jun;21(12):4032-45.

32.

The dynein heavy chain gene family in Tetrahymena thermophila.

Xu W, Royalty MP, Zimmerman JR, Angus SP, Pennock DG.

J Eukaryot Microbiol. 1999 Nov-Dec;46(6):606-11.

PMID:
10568033
33.

New axonemal dynein heavy chains from Tetrahymena thermophila.

Mobberley PS, Sullivan JL, Angus SP, Kong X, Pennock DG.

J Eukaryot Microbiol. 1999 Mar-Apr;46(2):147-54.

PMID:
10361736

Supplemental Content

Loading ...
Support Center